Therefore, it is reasonable to hypothesize that therapies blocking inflammatory cytokines, such as monoclonal antibodies specific for TNF-α and the IL-6 receptor, could be useful to reset systemic immunity and possibly other important manifestations of the disease in WS patients. This evidence concerns the gene TNF and Werner syndrome.